- £135.32m
- £130.18m
- £13.61m
Annual income statement for Bioventix, fiscal year end - June 30th, GBP millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | UAS | UAS | UAS | UAS | UAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10.3 | 10.9 | 11.7 | 12.8 | 13.6 |
| Cost of Revenue | |||||
| Gross Profit | 9.49 | 10.1 | 11 | 12 | 12.7 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2.13 | 2.84 | 2.45 | 2.78 | 3.21 |
| Operating Profit | 8.18 | 8.09 | 9.27 | 10 | 10.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 8.23 | 8.12 | 9.28 | 10.1 | 10.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 7.2 | 6.73 | 7.67 | 8.37 | 8.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 7.2 | 6.73 | 7.67 | 8.37 | 8.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 7.2 | 6.73 | 7.67 | 8.37 | 8.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.38 | 1.28 | 1.46 | 1.58 | 1.55 |
| Dividends per Share | |||||
| Special Dividends per Share |